ESC 365 - LDLc reduction with fixed-dose combination rosuvastatin-ezetimibe in patients with coronary heart disease that are not candidates for PCSK9 inhibitors treatment

ESC Premium Access

LDLc reduction with fixed-dose combination rosuvastatin-ezetimibe in patients with coronary heart disease that are not candidates for PCSK9 inhibitors treatment

Session: Risk Factors and Prevention ePosters

Topic: Drug therapy

Speaker: Doctor A. Cordero (Sant Joan d'Alacant, ES)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Alberto Cordero

UNIVERSITY HOSPITAL SAN JUAN DE ALICANTE, Sant Joan d'Alacant (Spain)

4 presentations

0 follower

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Access the full session

Risk Factors and Prevention ePosters

Speakers: Doctor A. Cordero, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

Open Access

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

27 August 2021

ESC Premium Access

The HEP-COVID Trial

27 August 2021

ESC 365 is supported by